Skip to main content
SpringerLink
Log in

Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro

  • Original Articles
  • Adryamicin, Analogues, DNA, Protein Synthesis
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Drug-DNA binding is claimed to be the basis by which the antitumor antibiotic adriamycin (doxorubicin) inhibits DNA and RNA synthesis in vitro. However, in preliminary studies the DNA-non-binding adriamycin analogue N-trifluoroacetyladriamycin-14-valerate (AD 32) showed somewhat greater inhibition of DNA and RNA synthesis than adriamycin under identical conditions. The kinetics of macromolecule synthesis inhibition induced by adriamycin and AD 32, and the two principal DNA-nonbinding metabolites of AD 32, N-trifluoroacetyladriamycin (AD 41) and N-trifluoroacetyladriamycinol (AD 92), have now been subjected to comparative study in cultured CEM (human leukemic lymphoblastic) cells. At equimolar concentrations (10 μM), or at concentrations related to their 50% growth-inhibitory values vs CEM cells, AD 32 was consistently found to be more inhibitory than adriamycin of DNA and RNA synthesis, as measured by the incorporation of tritiated thymidine and uridine, respectively, into acid-precipitable fractions relative to untreated controls. Marked inhibitory actibity was apparent with 10 μM AD 32 even at the earliest sampling time (15 min); with adriamycin at the same concentration the maximal effect was not achieved until 3 h. AD 32 at 4.8 μM concentration continued to show strong inhibition of nucleic acid synthesis, whereas adriamycin at 1.0 μM was essentially inactive. Like AD 32, AD 41 and AD 92 showed greater inhibition than adriamycin of DNA and RNA synthesis at the early sampling times, although in all instances the effects of AD 32 were more profound. AD 32 at 10 μM concentration produced a moderate but significant inhibition of the incorporation of tritiated methionine into protein compared with adriamycin, which at this concentration was not active. Parallel HPLC analytical studies with simillar drug-treated cultures indicated that, while small amounts of adriamycin were found in cells treated with 10 μM AD 32, the amount of adriamycin present at 15 min was only a small fraction (<5%) of the amount of adriamycin achieved at 3 h in cultures treated with 1.0 μM adriamycin, a concentration already shown to be only slightly inhibitory of nucleic acid synthesis under the culture conditions. The present study thus confirms the marked DNA and RNA synthesis-inhibitory effects of AD 32, and establishes that this inhibitory activity is not due to conversion of AD 32 into adriamycin. These findings accordingly call into question the validity of the drug-DNA binding mechanism as the explanation for the nucleic acid synthesis inhibitory effects seen with ADR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ADR:

adriamycin (doxorubicin)

AD 32:

N-trifluoroacetyladriamycin-14-valerate

AD 41:

N-trifluoroacetyladriamycin

AD 92:

N-trifluoroacetyladriamycinol

AMNOL:

adriamycinol

AD 48:

adriamycin-14-valerate

AD 60:

13-dihydro-N-trifluoroacetyladriamycin-14-valerate

HPLC:

high-performance liquid chromatography

DMSO:

dimethyl sulfoxide

TCA:

trichloroacetic acid

ID50 :

50% growth-inhibitory value relative to untreated controls

References

  1. Baserga R (1962) A study of nucleic acid synthesis in ascites tumor cells by two-emulsion autoradiography. J Cell Biol 12: 633

    Google Scholar 

  2. Blum RH, Garnick MB, Israel M, Cannellos GP, Henderson IC, Frei E III (1979) An initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD 32), an adriamycin analog. Cancer Treat Rep 63: 919

    Google Scholar 

  3. Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E III (1981) Preclinincal rationale and phase I clinical trial of the adriamycin analog, AD 32. In: Carter SK, Sakurai Y, Umezawa H (eds) New drugs in cancer chemotherapy. Springer, Berlin Heidelberg New York, p 7

    Google Scholar 

  4. Brox L, Gowans B, Belch A (1980) N-Trifluoroacetyladriamycin-14-valerate and adriamycin induce DNA damage in the RPMI-6410 human lymphoblastoid cell line. Can J Biochem 58: 720

    Google Scholar 

  5. Chabner BA, Myers CE (1982) Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia, p 180

    Google Scholar 

  6. Chuang LF, Kawahata RT, Chuang RY (1980) Inhibition of chicken myeloblastosis RNA polymerase II activity in vitro by N-trifluoroacetyladriamycin-14-valerate. FEBS Lett 117: 247

    Google Scholar 

  7. Chuang RY, Chuang LF, Kawahata RT, Israel M (1983) Effects of N-trifluoroacetyladriamycin-14-valerate on [3H]-thymidine uptake and DNA synthesis of human lymphoma cells. J Biol Chem 258: 1062

    Google Scholar 

  8. Dantchev D, Balercia G, Bourut C, Anjo J, Maral R, Mathe G (1984) Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs. Biomed Pharmacother 38: 322

    Google Scholar 

  9. DiMarco A (1975) Adriamycin (NSC-123127): mode and mechanism of action. Cancer Chemother Rep [3] 6: 91

    Google Scholar 

  10. DiMarco A (1982) Anthracycline antibiotics. In: Holland JF, Frei E III (eds) Cancer medicine, 2nd edn. Lea and Febiger, Philadelphia, p 872

    Google Scholar 

  11. DiMarco A, Arcamone F (1975) DNA complexing antibiotics: daunomycin, adriamycin, and their derivatives. Arzneimittelforsch 25: 368; see also earlier references cited therein

    Google Scholar 

  12. Fachinetti T, Mantovani A, Cantoni L, Cantoni R, Salmona M (1978) Intercalation with DNA is a prerequisite for daunomycin, adriamycin, and its congeners in inhibiting DNase. I. Chem Biol Interact 20: 97

    Google Scholar 

  13. Feinendegen LE, Bond VP, Painter RB (1961) Studies on the interrelationship of RNA synthesis, DNA synthesis, and precursor pools in human tissue culture cells studied with tritiated pyrimidine nucleosides. Exp Cell Res 22: 381

    Google Scholar 

  14. Garnick MB, Israel M, Pegg WJ, Blum RH, Smith E, Frei E III (1979) Hepatobiliary pharmacokinetics of AD 32 in man. Proc AACR/ASCO 20: 206

    Google Scholar 

  15. Garnick MB, Griffin JD, Sack MJ, Blum RH, Israel M, Frei E III (1982) Phase II evaluation of N-trifluoroacetyladriamycin-14-valerate (AD 32). In: Muggia FM, Young CW, Carter SK (eds) Anthracline antibiotics in cancer therapy. Nijhoff, The Hague, p 541

    Google Scholar 

  16. Goodman MF, Lee GM, Bachur NR (1977) Adriamycin interactions with T4 DNA polymerase. J Biol Chem 252: 2670

    Google Scholar 

  17. Henderson IC, Billingham M, Israel M, et al. (1978) Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits. Proc AACR/ASCO 19: 158

    Google Scholar 

  18. Israel M, Idriss JM (1982) A possible mechanistic basis for the growth-inhibitory properties of N-trifluoroacetyladriamycin-14-valerate (AD 32), a non-DNA binding adriamycin (ADR) analog. Proc 13th Int Cancer Congress Seattle, WA, p 245

  19. Israel M, Modest EJ (1977) N-Trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same. U. S. Patent No. 4,035,566

  20. Israel M, Modest EJ, Frei E III (1975) N-Trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35: 1365

    Google Scholar 

  21. Israel M, Pegg WJ, Seshadri R, Parker LM (1976) N-Trifluoroacetyladriamycin-14-valerate (AD 32): some in vivo structure-activity relationships. Abstracts, 5th International Symposium on Medicinal Chemistry, Paris, France, p 63

  22. Israel M, Garnick MB, Pegg WJ, Blum RH, Frei E III (1978a) Preliminary pharmacology of AD 32 in man. Proc AACR/ASCO 19: 160

    Google Scholar 

  23. Israel M, Pegg WJ, Wilkinson PM (1978b) Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate. J Pharmacol Exp Ther 204: 696

    Google Scholar 

  24. Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1978c) Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liquid Chromatogr 1: 795

    Google Scholar 

  25. Israel M, Wilkinson PM, Pegg WJ, Frei E III (1978d) Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat. Cancer Res 38: 365

    Google Scholar 

  26. Israel M, Khetarpal VK, Potti PGG, Seshadri R (1980a) Distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) in tissues of A/JAX mice. Proc AACR/ASCO 21: 256

    Google Scholar 

  27. Israel M, Wilkinson PM, Osteen RT (1980b) Pharmacology studies with adriamycin and N-trifluoroacetyladriamycin-14-valerate (AD 32) in cynomolgus monkeys: additional evidence for the absence of an adriamycin-prodrug mechaanism for AD 32. In: Crooke ST, Reich SD (eds) Anthracyclines: current status and new developments. Academic Press, New York, p 431

    Google Scholar 

  28. Israel M, Potti PG, Seshadri R (1985) Adriamycin analogues. Rationale, synthesis, and preliminary antitumor evaluation of highly-active DNA-nonbinding N-(trifluoroacetyl)adriamycin-14-O-hemiester derivatives. J Med Chem 28: 1223

    Google Scholar 

  29. Israel M, Idriss JM, Seshadri R (1986) In vitro studies with N-benzyladriamycin-14-valerate (AD 198), a new anthracycline analog. Abstracts 14th Int Cancer Congress Budapest, Hungary, vol 1, p 159

    Google Scholar 

  30. Kanter PM, Schwartz HS (1979) Effects of N-trifluoroacetyladriamycin-14-valerate and related agents on DNA strand damage and thymidine incorporation in CCRF-CEM cells. Cancer Res 39: 448

    Google Scholar 

  31. Khetarpal VK, Israel M (1982) Metabolism and disposition of N-trifluoroacetyladriamycin-14-valerate in mice bearing Lewis lung carcinoma. Fed Proc 41: 1572

    Google Scholar 

  32. Krishan A, Israel M, Modest EJ, Frei E III (1976) Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Res 36: 2114

    Google Scholar 

  33. Krishan A, Dutt K, Israel M, Ganapathi R (1981) Comparative effects of adriamycin and AD 32 on cell cycle traverse, chromosomal damage, and macromolecule synthesis in vitro. Cancer Res 41: 2745

    Google Scholar 

  34. Lazarus H, Yuan G, Tan E, Israel M (1978) Comparative inhibitory effects of adriamycin, AD 32, and related comhibitory effects of adriamycin, AD 32, and related compounds on in vivo cell growth and macromolecular synthesis. Proc AACR/ASCO 19: 159

    Google Scholar 

  35. Levin M, Silber R, Israel M, Goldfeder A, Khetarpal VK, Potmesil M (1981) Protein-associated DNA breaks and DNA-protein crosslinks caused by DNA non-binding derivatives of adriamycin in L1210 cells. Cancer Res 41: 1006

    Google Scholar 

  36. Parker LM, Hirst M, Israel M (1978) N-Trifluoroacetyladriamycin-14-valerate (AD 32): additional mouse antitumor and toxicity studies. Cancer Treat Rep 62: 119

    Google Scholar 

  37. Pearlman LF, Chuang RY, Israel M, Simpkins H (1986) The interaction of three second generation anthracyclines with polynucleotides, RNA, DNA, and nucleosomes. Cancer Res 46: 341

    Google Scholar 

  38. Potmesil M, Levin M, Israel M, Silber R (1982) Protein-associated DNA breaks caused by adriamycin or N-trifluoroacetyladriamycin-14-valerate in vivo: relationship to cell clonogenicity. In: Periti P, Grassi G (eds) Current chemotherapy and immunotherapy. American Society for Microbiology, Washington, DC, p 1439

    Google Scholar 

  39. Potmesil M, Levin M, Traganos F, Israel M, Darzynkiewicz Z, Khetarpal VK, Silber R (1983) In Vivo effects of adriamycin or N-trifluoroacetyladriamycin-14-valerate on a mouse lymphoma. Eur J Cancer Clin Oncol 19: 109

    Google Scholar 

  40. Sengupta SK, Seshadri R, Modest EJ, Israel M (1976) Comparative DNA-binding studies with adriamycin (ADR), N-trifluoroacetyladriamycin-14-valerate (AD 32), and related compounds. Proc Am Assoc Cancer Res 17: 109

    Google Scholar 

  41. Sinha BK, Sik RH (1980) Binding of [14C]-adriamycin to cellular macromolecules in vivo. Biochem Pharmacol 29: 1867

    Google Scholar 

  42. Tatsumi K, Nakamura T, Wakisaka G (1974) Comparative effects of daunomycin and adriamycin on nucleic acid metabolism in leukemic cells in vitro. Gann 65: 237

    Google Scholar 

  43. Vecchi A, Cairo M, Mantovani A, Sironi M, Spreafico F (1978) Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Treat Rep 62: 111

    Google Scholar 

Download references

Author information

Author notes

  1. Vinod K. Khetarpal

    Present address: Drug Disposition Department, Rorer Central Research, 19044, Horsham, PA

Authors and Affiliations

  1. Department of Pharmacology, The University of Tennessee-Memphis, 38163, Memphis, TN, USA

    Mervyn Israel, John M. Idriss, Yoshihiro Koseki & Vinod K. Khetarpal

  2. Medicinal Chemistry, The University of Tennessee-Memphis, 38163, Memphis, TN, USA

    Mervyn Israel, John M. Idriss, Yoshihiro Koseki & Vinod K. Khetarpal

Authors
  1. Mervyn Israel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Idriss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiro Koseki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vinod K. Khetarpal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Israel, M., Idriss, J.M., Koseki, Y. et al. Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro. Cancer Chemother. Pharmacol. 20, 277–284 (1987). https://doi.org/10.1007/BF00262577

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262577

Keywords

Search

Navigation